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Abstract 
Ethnopharmacological relevance: Citrus aurantium L. (Rutaceae) is used, either singly or as 
a part of a polyherbal preparation, in Nigerian traditional medicine for the management of 
cancer and inflammatory diseases. Currently, there is a dearth of knowledge demonstrating its 
anticancer potential. 
Aim of the study: This study was carried out to determine the in vitro cytotoxicity of the crude 
extract of the stem bark of C. aurantium, identify and isolate the bioactive constituents and to 
establish the cytotoxicity of such constituents.   
Material and Methods The powdered bark of C. aurantium was extracted with methanol at 
room temperature (25-34 °C) and the crude extract was partitioned successively, with n-
hexane, dichloromethane (DCM) and methanol. Amongst the fractions, the DCM fraction was 
the most active and compounds were isolated from this fraction using several chromatographic 
techniques. The structures of the isolated compounds were elucidated by spectroscopic means 
(mass spectrometry, one-dimensional and two-dimensional nuclear magnetic resonance). The 
cytotoxicity of the extract, and the isolated compounds were evaluated by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) assay against four human cancer cell lines: 
A549 (lung), HepG2 (liver), MCF7 (breast) and PC3 (prostate). The selectivity of the isolated 
compounds was assessed using the normal human prostate epithelium cells (PNT2).  
Results and Discussion: Of the three plant fractions, the DCM fraction showed significant 
cytotoxicity, with its highest activity against A549 cells (IC50 = 3.88 µg/mL) and the least 
activity on HepG2 cells (IC50 = 5.73 µg/mL). Six acridone alkaloids: citrusinine-I (1), 
citracridone-I (2), 5-hydroxynoracronycine (3), natsucitrine-I (4), glycofolinine (5) and 
citracridone-III (6), were isolated from the DCM fraction of C. aurantium. The isolated 
compounds demonstrated potent to moderate cytotoxicity ((IC50 = 12.65 – 50.74 µM) against 
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the cancer cells under investigation. It is noteworthy that the compounds exerted cytotoxicity 
at least four times more selective towards the carcinoma cells than the PNT2 cells.  
Conclusion: The results obtained from this study have provided some evidence for the 
ethnomedicinal use of C. aurantium against cancer and the acridone alkaloids present in its 
stem bark, have appeared to be responsible for this effect. Further research to explore the 
underlying molecular mechanism of the isolated acridone alkaloids is needful. 
 Keywords: Citrus aurantium; Rutaceae; acridone alkaloids; cytotoxicity, MTT assay 
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spectroscopy; HMBC, heteronuclear multiple bond correlation; NOESY, nuclear Overhauser 
effect spectroscopy; DEPTQ, distortionless enhancement by polarisation transfer; FBS, foetal 
bovine serum; FHI, forest herbarium Ibadan; IR, infrared spectroscopy; m/z, mass to charge 
ratio; WHO, world health organisation; Hz, hertz; CC, column chromatography; HSQC, 
homonuclear single quantum correlation; UV, ultraviolet spectroscopy 
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1. Introduction 
Citrus aurantium L. (Rutaceae), commonly known as bitter orange or sour orange (local name 
in Yoruba, South West Nigeria, “Osan gaingain”), is used in traditional medicine to treat 
cancer, diabetes, malaria, typhoid and worm infestations (Arias and Ramón-Laca, 2005). The 
fruit extract of C. aurantium is used traditionally for the management anorexia and obesity. A 
protoalkaloid, p-synephrine is the most important bioactive compound present in the fruits of 
this plant (Stohs et al., 2011). This compound, due to its β-adrenergic activity, is responsible 
for the reduction in appetite and weight gain associated with the folklore use of C. aurantium. 
Hordenine, N-methyltyramine, octopamine and tyramine are other adrenergic amines present 
in small amount, also contribute to the weight reduction activity of C. aurantium (Fugh-Berman 
and Myers, 2004; Pellati and Benvenuti, 2007). There have been conflicting reports concerning 
the safety of C. aurantium extracts and p-synephrine. While some studies associated the anti-
obesity effects of C. aurantium with reduction of locomotor activity and cardiovascular toxicity 
in mice and rats (Calapai et al., 1999; Arbo et al., 2008; Arbo et al., 2009), several clinical 
studies have shown that C. aurantium extract (at a dose of approximately 49 mg p-synephrine 
daily) displayed no adverse effects on the blood pressure, blood chemistries, 
electrocardiogram, heart rate, hepatic function and renal function (Kaats et al., 2013). Previous 
ethnopharmacological studies have revealed that C. aurantium possesses several useful 
biological activities which are summarised in Table 1. 
Typical of the Citrus species, several flavonoids with antioxidant and anti-inflammatory 
activities have been isolated from various parts of C. aurantium (Rio et al., 1992; Barreca et 
al., 2011; Zhao et al., 2012). The seeds of C. aurantium are  rich in limonoid glucosides; notably 
isolimonic acid, ichangin, limonin glucoside, deacetylnomilin glucoside and obacunone 
glucoside (Bennett et al., 1991). The triterpenoid, ichanexic acid, isolated from the ground 
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seeds of C. aurantium had significant chemopreventive activities on  human colon cancer cells 
(Jayaprakasha et al., 2008).   
In our search for cytotoxic agents from natural sources, we have recently carried out an 
ethnobotanical survey of medicinal plants used for cancer treatment amongst the Ijebu ethnic 
group of southwestern Nigeria, and several traditional healers mentioned C. aurantium, as part 
of herbal recipes for the treatment of cancer (Segun et al., 2018). Other studies within the same 
region documented the anticancer ethnomedicinal use of C. aurantium (Soladoye et al., 2010; 
Olujimi et al., 2014). Although C. aurantium is not indigenous to Nigeria, it has become a 
widely used medicinal plant in the country.  
This study was carried out to determine the in vitro cytotoxicity of the crude extract of the stem 
bark of C. aurantium, identify and isolate the bioactive constituents and to establish the 
cytotoxicity of such constituents. In the present study, the cytotoxicity of the stem bark of C. 
aurantium on four human cancer cell lines: breast (MCF7), liver (HepG2), lung (A549) and 
prostate (PC3) carcinoma cells in addition to the isolation and structural elucidation of six 
known acridone cytotoxic alkaloids (1-6) are reported. 
2. Material and methods 
2.1 Instrumentation 
Ultra Violet (UV) spectra were obtained on an Analytik Jena UV Visible spectrophotometer 
(Germany) in methanol (MeOH). Infra-red (IR) spectra were recorded on a PerkinElmer FTIR 
Spectrum BX spectrometer. Proton (1H) and 13C NMR spectra (1D and 2D experiments) were 
recorded on the Bruker Avance III Spectrometer at 600 and 150 MHz, respectively. Chemical 
shifts were reported in δ (ppm) using CDCl3 as the internal standard and the coupling constants 
(J) are measured in Hertz (Hz). Mass spectrometric (HR-EI-MS) data were measured using the 
Thermo Scientific LTQ Orbitrap XL mass spectrometer. Analytical TLC was performed using 
pre-coated silica gel 60 F254 aluminium foil (Sigma-Aldrich, Germany) and spots were 
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visualised 254 nm after spraying with p-anisaldehyde-sulphuric acid reagent and heated at 70 
°C. The HPLC analysis was performed on an Agilent 1260 infinity HPLC System coupled with 
an Agilent 1260 diode array detector using an Ace-5 C18 column (150 × 21.2 mm, 5 µm 
particle size, Hichrom Ltd) and HPLC grade solvents were purchased from Fischer Scientific 
(Loughborough, UK). Absorbance measurements for the MTT assay were taken on a CLARIO 
star microplate reader (BMG labtech, Germany). 
2.2 Cell culture materials 
Human adenocarcinoma cell lines: breast (MCF7), liver (HepG2), lung (A549) and prostate 
(PC3) were purchased from the American Type Culture Collection (ATCC), (LGC Standards, 
Middlesex, UK), and the normal human immortalised prostate cell line (PNT2) was obtained 
from the European Collection of Authenticated cell cultures (ECACC), (Public Health 
England, Salisbury, UK). Cell culture materials including Dulbecco’s Modified Eagle Medium 
(DMEM), foetal bovine serum (FBS) and trypsin were obtained from Biosera (Nauaille, 
France). Chemicals including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT), 
vinblastine, trypan blue, phosphate buffered-saline (PBS) tablets and penicillin-streptomycin 
antibiotics suspension were purchased from Sigma-Aldrich (Dorset, UK). 
2.3 Plant material 
Fresh stem bark of C. aurantium was purchased at the Bode herb market, Ibadan, Nigeria in 
July 2016. The material was identified and authenticated at the Forest Herbarium Ibadan, 
Nigeria, where a voucher specimen (FHI 111229) was deposited. The botanical name of the 
plant was verified on the plant list database (http://www.theplantlist.org/; accessed 
29/10/2016). 
2.4 Extraction and isolation of active compounds 
The air-dried and powdered stem bark of C. aurantium (1 kg) was extracted with MeOH (5 L 
x 2) at room temperature (25-34 °C) with continuous stirring for 72 h. The combined filtrate 
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was concentrated under reduced pressure at 40 °C to give a dark brown crude extract (138 g). 
A portion of this crude extract (80 g) was dissolved in MeOH (140 mL) and suspended in H2O 
(60 mL) and partitioned successively with n-hexane (200 mL x 5), dichloromethane (DCM) 
(200 mL x 5) and methanol (MeOH) (200 mL x 5). The DCM fraction (5 g) was subjected to 
vacuum liquid chromatography (VLC) on silica gel (5 x 30 cm; < 55 in size) and eluted with 
gradient mixtures of DCM/MeOH (10:1 to 5:5, each 250 mL). A total of 10 sub-fractions were 
collected and pooled into four main fractions (Fractions A-D), based on analytical TLC profiles 
of the fractions. 
Fraction C (2 g) was chromatographed over a silica column gel (5 x 30 cm; 63–200 µm) and 
successively eluted with n-hexane/EtOAc (3:7 to 1:10) and EtOAc/MeOH (1:10 to 5:5) by 
gradient elution. A total of 180 sub fractions of (100 mL each), were collected and pooled into 
16 sub-fractions (Sub-Fractions 1 - 16). Sub-fraction 3 (121 mg) was purified on reversed phase 
preparative HPLC (mobile phase H2O/MeOH containing 0.1 trifluoroacetic acid (TFA); 0-5 
min: 30-50% MeOH, 5-20 min: 50-80% MeOH, 20-30 min: 80-100% MeOH, 30-35 min: 
100% MeOH, 35-40 min: 30% MeOH) to afford citrusinine-I (1, 7.7 mg; tR=12.3 min), 
citracridone-I (2, 9.7 mg; tR=19.3 min) and 5-hydroxynoracronycine (3, 7.3 mg; tR=21.8 min). 
Each time, UV detection were at 220, 254, and 320 nm and the flow rate was maintained at 10 
mL/min. Sub-fraction 4 (81 mg) was purified on RP-Prep HPLC (mobile phase H2O/MeOH 
containing 0.1 TFA; 0-30 min: 40-100% MeOH, 30-35 min: 100% MeOH, 35-40 min: 40% 
MeOH) to afford natsucitrine-I (4, 6.4 mg; tR=15.1 min). Sub-Frac 5 (86 mg) was purified on 
RP-Prep HPLC (mobile phase H2O/MeOH containing 0.1 TFA; 0-3 min: 30-75% MeOH, 3-
30 min: 75-100% MeOH, 30-33 min: 100% MeOH, 33-38 min: 30% MeOH) to afford 
glycofolinine (5, 7.1 mg, tR=14.1 min). Sub-fraction 6 (91 mg) was purified on RP-PREP 
HPLC (mobile phase H2O/ACN containing 0.1 TFA; 0-3 min: 30-50% ACN, 3-30 min: 50-
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100% ACN, 30-33 min: 100% ACN, 33-38 min: 30% ACN) to afford citracridone-III (6, 9.9 
mg, tR=13.2 min).  
2.5 Cytotoxicity studies 
2.5.1 Cell lines and cell culture 
Human cancer cell lines: A549 (lung), HepG2 (liver), MCF7 (breast) and PC3 (prostate) 
alongside the normal prostate epithelium cells (PNT2) were cultured in T75 flasks containing 
DMEM supplemented with 10% FBS and 1% penicillin-streptomycin antibiotics suspension. 
The cells were maintained in a humidified atmosphere, containing 5% CO2 at 37 °C and 
passaged bi-weekly at a 1:3 dilution using 0.05% trypsin - 0.02% EDTA in PBS. Changes in 
cell morphology, corresponding to the effects of test compounds, were monitored through an 
inverted microscope (40x and 100x, Olympus CKX41, UK). Cells were counted using an 
automated haemocytometer (C-Chip NanoEnTek, USA). 
2.5.2 Preparation of extracts and compounds 
Plants extracts and fractions were solubilised in 100% dimethyl sulfoxide (DMSO), to give a 
stock solution (SS) of 100 mg/mL. Uniformity of the solution was ensured by stirring with 
vortex agitation (1 min) prior to use. From the SS, serial dilutions were made in the cell culture 
media to obtain working concentrations of 100, 20, 4, 0.8 and 0.16 µg/mL. For the pure 
compounds, a SS of 10 M was prepared in 10% DMSO solution, thereafter, serial dilutions 
were made to give working concentrations of 100, 50, 25, 12.5 and 6.25 µM for treatment with 
MCF7, HepG2, A549 and PC3, and working concentrations of 800, 400, 200, 100 and 50 µM 
for treatment with PNT2. For vinblastine (positive control), a SS of 10 µM was prepared in 
10% DMSO solution, thereafter, serial dilutions were made to give working concentrations of 
100, 50, 25, 12.5, 6.25 nM. Dilutions of the SS were made in cell culture media with the final 
concentration of DMSO not exceeding 0.1%, which had previously been found not to be 
cytotoxic (Basar et al., 2015). 
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2.5.3 Colorimetric MTT in vitro assay 
Cytotoxicity testing was carried out using the MTT assay, which determines the number of 
viable cells in culture (Gerlier and Thomasset, 1986). After repeated initial experiments, the 
cell densities for optimal growth were found to be 2 x 104, 4 x 104, 1.2 x 104, 2 x 104 and 4 x 
104 cells/well for MCF7, HepG2, A549, PC3 and PNT2, respectively. The exponential phases 
of the cell lines were seeded into flat-bottomed, 24-well plate (Corning Costar® TC-treated, 
Merck, UK) and incubated at 37°C/5% CO2 for 24 h to allow the cells to adhere to the surface 
of the plate. After reaching about 90% confluence at 24 h, the old medium was removed by 
vacuum suctioning, and the cells treated with varying concentrations (1 mL each) of the 
extract(s), fraction(s) and compound(s), and incubated for 72 h. The first five wells of the 24-
well plate (A1-A5) contained the various concentrations of the test 
extract/fractions/compounds, while the last well (A6) contained only 1 mL of the DMSO-
growth medium (negative control). The experiment was conducted in quadruplicate for each 
test dilution, so that wells A1-D1, A2-D2, A3-D3, A4-D4 and A5-D5 contained different 
concentrations of the extract/fractions/compounds. At the expiration of the incubation period, 
the MTT assay was performed to measure the cell viability. The protocol described earlier in 
the literature was adopted with slight modifications (Ogbole et al., 2017). Briefly, the old 
medium was removed from each well by vacuum suctioning and replaced with 1 mL of 500 
µg/mL MTT dye in PBS. The plates were incubated for 2 h at 37°C/5% CO2 to allow the 
production of formazan crystals. After incubation, the medium was removed by vacuum 
suctioning and 500 µL of propanol was added, under light protection, to dissolve the dark blue 
formazan crystals. The plates were placed on a shaker for 10 min to enhance the dissolution of 
preformed formazan crystals. The dilution in each 24-well plate was transferred into a 96 well 
plate, so that the solution in A1 (24-well) was transferred to A1-A4 (96-well), B1 (24-well) 
was transferred to B1-B4 (96-well) and so on. The absorbance of the solution was measured at 
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570 nm on a Clario Star microplate reader. The average optical density (OD) obtained from the 
negative control wells was set arbitrarily at 100% and the average OD of treatment wells was 
calculated relative to the negative control. In addition, the same process was carried out for 
vinblastine (positive control) using the concentration range mentioned above. The cell viability 
was calculated as follows: 
 
% Inhibition =
Average OD(control)−Average OD(treated)
Average OD(control)
 x 100 
 2.6 Statistical analysis 
The results obtained were expressed as mean ± standard errors of means (SEM). The 
experiments were conducted in quadruplicate on three different occasions. Statistical analysis 
was done using GraphPad (version 5.01, GraphPad Prism Software Inc., San Diego, CA). One-
way analysis of variance (ANOVA) followed by Tukey’s test (each treatment compared to 
control) were used to test for the statistical differences between the groups. Differences 
between means were considered statistically significant when P<0.05. Inhibitory 
concentrations at (IC50) were obtained from graphs plotted using non-linear regression equation 
log (inhibitor) versus response - variable slope. 
3. Results and discussion 
3.1 Structure determination  
As the DCM fraction of C. aurantium was the most cytotoxic, the activity-guided fractionation 
of this fraction was performed using several chromatographic techniques, including vacuum 
liquid chromatography (VLC), column chromatography and HPLC to afford compounds 1-6.  
Spectroscopic analysis, mainly, 1H NMR, 13C NMR, 13C DEPTQ, 1H-13C HSQC, 1H-13C 
HMBC and 1H-1H NOESY and mass spectrometry (MS) were used to unambiguously elucidate 
the structures of the isolated compounds. All spectral data were  compared with the published 
literature data and the compounds were identified as citrusinine-I (1) (Wu and Furukawa, 
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1983), citracridone-I (2) (Wu et al., 1983), 5-hydroxynoracronycine (3) (Wu and Furukawa, 
1983; Yamamoto et al., 1989), natsucitrine-I (4) (Juoichi et al., 1985), glycofolinine (5) (Ono 
et al., 1995) and citracridone-III (6) (Yamamoto et al., 1989). This is the first report of the 
isolation of these compounds from C. aurantium, though they have been reported from other 
Citrus spp (C. sinensis (L.) Osbeck, Wu and Furukawa, 1983; C. reticulata Blanco, Wu et al., 
1983; C. natsudaidai (Yu. Tanaka) Hayata, Juoichi et al., 1985; C. sinensis (L.) 
Osbeck,Yamamoto et al., 1989).  
 
 
 
Figure 1: Structures of compounds 1-6 
 
Citrusinine-I (1): pale yellow amorphous powder; UV (MeOH) λmax (log ε) 208 (0.13), 266 
(015), 320 (0.07), 418 (0.02) nm; IR (KBr) νmax 3241, 2966, 1625, 1588, 1563, 1462, 1384, 
1128, 1103 cm-1; positive HRESIMS m/z 302.1030 [M+H]+ (calcd for C16H16NO5, 302.1028);
 
1H-NMR and 13C-NMR (600/150 MHz, in CDCl3) shown on Tables 2 and 3, respectively. 
Citracridone-I (2): orange amorphous powder; UV (MeOH) λmax (log ε) 202 (0.57), 268 
(0.79), 328 (0.27) nm; IR (KBr) νmax 3199, 2967, 2643, 1681, 1625, 1587, 1566, 1174, 1129 
cm-1; positive HRESIMS m/z 354.1338 [M+H]+ (calcd for C20H20NO5, 354.1336);
  1H-NMR 
and 13C-NMR (600/150 MHz, in CDCl3) shown on Tables 2 and 3, respectively. 
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5-hydroxynoracronycine (3): yellow amorphous powder; UV (MeOH) λmax (log ε) 208 (0.08), 
266 (0.09), 284 (0.09), 322 (0.04), 418 (0.01) nm; IR (KBr) νmax 3250, 2960, 1625, 1588, 1563, 
1359, 1128, 1103 cm-1; positive HRESIMS m/z 324.1233 [M+H]+ (calcd for C19H18NO4, 
324.1230);  1H-NMR and 13C-NMR (600/150 MHz, in CDCl3) shown on Tables 2 and 3, 
respectively. 
Natsucitrine-I (4): yellow amorphous powder; UV (MeOH) λmax (log ε) 268 (1.28), 330 (0.33), 
384 (0.17) nm; IR (KBr) νmax 3197, 2967, 2646, 1680, 1625, 1556, 1481, 1174, 1129 cm-1; 
positive HRESIMS m/z 302.1025 [M+H]+ (calcd for C16H16NO5, 302.1023);
 1H-NMR and 13C-
NMR (600/150 MHz, in CDCl3) shown on Tables 2 and 3, respectively. 
Glycofolinine (5): yellow amorphous powder; UV (MeOH) λmax (log ε) 272 (2.36), 346 (0.65) 
nm; IR (KBr) νmax 3194, 2967, 2646, 1680, 1625, 1566, 1480, 1174, 1129 cm-1; positive 
HRESIMS m/z 332.1131 [M+H]+ (calcd for C17H18NO6, 332.1129);
  1H-NMR and 13C-NMR 
(600/150 MHz, in CDCl3) shown on Tables 2 and 3, respectively. 
Citracridone-III (6): yellow amorphous powder; UV (MeOH) λmax (log ε) 204 (2.01), 272.0 
(0.32) nm; IR (KBr) νmax 3241, 2966, 1625, 1588, 1564, 1462, 1384, 1128, 1103 cm-1; 1H-
NMR and 13C-NMR (600/150 MHz, in CDCl3) shown on Tables 2 and 3, respectively. 
 
3.2 Cytotoxicity assay 
The effects of the extract, fractions and isolated compounds of C. aurantium was tested on 
MCF7, HepG2, A549 and PC3 cell lines. These cell lines were selected for this study, because 
of high and increased in incidence rates of these cancers. The need to develop effective and 
safe chemotherapeutic agents as novel treatments cannot be over emphasised.  Breast, liver and 
lung cancers account for 60% of the cancer cases among women globally, while the prostate 
cancer is the most diagnosed cancer type in males (Torre et al., 2017). The DCM and MeOH 
fractions of the stem bark of C. aurantium were found to possess activity below 100 µg/mL 
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against the cancer cells while the n-hexane fraction was inactive at 100 µg/mL against the 
carcinoma cell lines (Table 4). However, only the DCM fraction had an activity that met the 
specification of the National Cancer Institute (NCI), which requires a crude plant 
extract/fraction to possess IC50 value < 30 µg/mL before it could be considered as active 
(Rajkapoor et al., 2007).  
Therefore, the DCM fraction was investigated further in this work. The DCM fraction showed 
highest activity against A549 cells (IC50 = 3.88 µg/mL) and displayed the least activity on 
HepG2 cells (IC50 = 5.73 µg/mL). The DCM fraction was subjected to further purification from 
which six acridone alkaloids were isolated. The MTT cell viability assay was used to determine 
the cytotoxicity of the fractions and the isolated compounds. This assay measures the ability of 
the mitochondrial enzyme, succinate dehydrogenase, to reduce the soluble tetrazolium 
containing yellow dye (MTT) into purple colour formazan crystals. Carcinoma cells rapidly 
divide and so display high degree of metabolic activity and aid a high degree of MTT reduction. 
The higher the number of viable cells in a culture, the higher the quantity of formazan that will 
be produced, and this gives an indication of the degree of cytotoxicity of the test 
extract/fraction/compound. Vinblastine, a reference compound used in several cytotoxicity 
evaluations, was included as a positive control. All test compounds elicited dose-dependent 
activity across the panel of human cancer cells (Figure 2), although with varying potencies as 
revealed by their IC50 values (Table 5). In addition, all the test compounds exhibited time-
dependent activity as the extent of morphological damage to the cells observed in the 
photomicrographs increased with prolonged exposure period. As the treatment time increased, 
cells showed progressive loss of normal elongated shape, shrunk to smaller round cells with a 
resultant loss of cell viability.  
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Fig 2: Concentration-dependent compound-induced reduction in the viability of MCF-7, HepG2, A549 and PC3. 
Cells were treated with a range of concentrations of the compounds for 72 h and the viability was assessed using 
MTT assay. Vinblastine was used as a reference standard, with IC50 of approximately 20 – 40 nM across the panel 
of carcinoma cells. According to the IC50 value, the rank order of increasing potencies of the compounds is 
citracridone-I (2) > citracridone-III (6) > 5-hydroxynoracronycine (3) > glycofolinine (5) > natsucitrine-I (4) > 
citrusinine-I (1). Values shown are means ± SEM (Standard error of the mean) of three different experiments. 
**P< 0.01 and ***P< 0.001, compared to the negative control (DMSO only), evaluated using the Tukey multiple 
comparison. X-axis: concentration in µM. 
 
The acridones examined in this study could be classified into two groups: tricyclic alkaloids (1 
(citrusinine-I), 4 (natsucitrine-I) and 5 (glycofolinine)) and tetracyclic alkaloids (2 
(citracridone-I), 3 (5-hydroxynoracronycine) and 6 (citracridone-III). Generally, the tetracyclic 
acridones displayed higher cytotoxicity towards the carcinoma cell lines than the tricyclic 
acridones. A similar pattern was observed in a previous work (Kawaii et al., 1999). Comparing 
the IC50 value for the cytotoxicity of the acridone alkaloids revealed important structural 
requirements for the observed activity. Citracridone-I which possess a methoxyl group at the 
C-5 position and a hydroxyl group at the C-6 position had the highest anti-proliferative activity 
(IC50 value = 12.5 – 14.8 μM) amongst the alkaloids. Citracridone-III which has a hydroxyl 
group attached to the C-5 position, unlike the methoxyl group of citracridone-I, had a reduced 
antiproliferative activity (IC50 value = 18.2 – 20.9 μM). Further investigation of the tetracyclic 
alkaloids revealed that 5-hydroxynoracronycine which lacked the hydroxyl group present in 
citracridone-III, had the least cytotoxic activity on the panel of cell carcinoma with IC50 value 
of 24.0 – 30.0 μM. Similar to the tetracyclic acridones, the presence of a methoxyl group and 
hydroxyl group at C-5 and C-6, respectively increase the cytotoxicity of the tricyclic acridones 
(glycofolinine > citrusinine-I; natsucitrine-I > citrusinine-I). In addition, methoxylation at the 
C-4 position enhances cytotoxicity (glycofolinine > natsucitrine-I). All the acridone studied in 
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this report had a hydroxyl group at the C-1 position. A previous study that examined the 
structure-activity relationships (SAR) of natural occurring acridones revealed that the 
intramolecular hydrogen bonding between the hydroxyl group on C-1 position and the peri-
carbonyl function of the acridone nucleus is necessary for antiproliferative activity as the 
replacement of the hydroxyl group with methoxyl group resulted in a marked decrease in 
cytotoxicity (Michael, 2008). All acridones studied displayed low activity towards the HepG2 
cells and high activity against MCF7 cells. 
Previous antiproliferative studies on citrusinine-I reported varying cytotoxicity towards tumour 
cells. An earlier report showed that citrusinine-I displayed a potent antiproliferative activity 
towards HL-60 cell line with an IC50 value of 8.6 µM according to the alamar blue assay (Braga 
et al., 2007), while another study reported an IC50 value less than 50 µM on HepG2 and KB 
cell lines according to the MTT assay (Teng et al., 2005). However, citrusinine-I did not show 
significant activity on COR-L23, C32, MCF7 and MRC-5 with IC50 value above 100 µM in 
the sulforhodamine-B assay (Braga et al., 2007). These differences might be the result of 
different cancer cell lines and cell proliferation methods used in the studies. Citracridone-I and 
5-hydroxynoracronycine were reported to display moderate cytotoxicity towards AU565, 
A431, SKBR-3 and T47D cell lines (Phetkul et al., 2014), while 5-hydroxynoracronycine 
exhibited a moderate antiproliferative activity towards PC3 cell line (Happi et al., 2011). In an 
in vitro assay of 12-O-tetradecanoylphorbol-13-acetate (TPA) induced Epstein–Barr virus 
early antigen (EBV-EA) activation assay, citrusinine-I and glycofolinine displayed a better 
anti-tumour promoting activity than β-carotene with IC50 value 300 mol ratio/TPA and 535 mol 
ratio/TPA respectively (Itoigawa et al., 2003). The cytotoxicity of natsucitrine-I is reported in 
this work for the first time. 
Several studies have reported the antiviral potentials of the acridone alkaloids studied in this 
paper. Glycofolinine displayed moderate activity against both HSV-1 and HSV-2 in 
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inactivation treatment and post-treatment with EC50 of 151 µM in both treatments 
(Chansriniyom et al., 2009). Another study revealed that citrusinine displayed an EC50 of 0.56 
µg/mL and 0.74 µg/mL against HSV-1 and HSV-2, respectively, while citracridone-I exhibited 
an EC50 of 1.3 µg/mL and 4.8 µg/mL against HSV-1 and HSV-2, respectively (Yamamoto et 
al., 1989). 5-Hydroxynoracronycine displayed a moderate anti-HIV-1 protease activity with an 
IC50 value of 93.1 μM (Panthong et al., 2013) and displayed remarkable inhibitory effects on 
Epstein-Barr virus activation (Takemura et al., 1995). 
The goal of cancer chemotherapy is the ability of chemotherapeutic agents for cancer to 
differentiate between cancer and normal human cells. Anticancer drugs are expected to exhibit 
selective toxicity, as this is needful to overcome noxious side effects associated with their 
usage. To measure the selectivity indices (SI) of the acridones used in this study, the normal 
human prostate cells (PNT2) was included in the present study. Vinblastine, the positive 
control, had a SI value ranging from 1.00 to 1.76 across the cancer cell lines, suggesting that 
the drug cannot sufficiently differentiate between normal and cancer cells, a result in agreement 
with a previous study (Ashidi et al., 2010). It is interesting to note that the cytotoxicity of these 
compounds was significantly lower toward the normal human cell line compared to the 
carcinoma cell lines (Table 6). The table revealed that the compounds exerted at least four 
times higher cytotoxicity towards the carcinoma cells than the PNT2 cells. Citracridone-I (2) 
had the highest SI value (approx. 7-13) across the panel of carcinoma cells, while citrusinine 
(1) displayed the lowest SI value (approx. 4-5) against the tumour cells. These results suggest 
that the acridone alkaloids have potentials in the development of low-toxicity chemotherapeutic 
agents.  
Citrus aurantium is widely used by traditional medical practitioners in southwestern Nigeria 
for the treatment of breast cancer, prostate cancer, wounds and other inflammatory diseases 
(Segun et. al., 2018). For the management of breast cancer, the stem bark of C. aurantium, 
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Entandrophragma utile (Dawe & Sprague) Sprague (Meliaceae) leaves, Annona muricata L. 
(Annonaceae) leaves and the roots of Xylopia aethiopica (Dunal) A. Rich. (Annonaceae) are 
boiled together in water for two hours. Three cups (approximately 20 mL per cup) of the 
decoction is taken thrice daily for one month. In addition, the stem bark of C. aurantium, 
Garcinia kola Heckel (Clusiaceae) fruits and Chrysophyllum albidum G.Don (Sapotaceae) 
fruits are grounded in a mortar and mixed with palm oil. The paste obtained is applied on the 
affected breast twice daily for up to two months. The result of the in vitro MTT assay has given 
credence to the ethnomedicinal use of this plant. However, it is expedient to carry out further 
in vivo toxicity studies to ascertain the safety of this medicinal plant, as a positive outcome 
from such research might lead to the development of low-toxicity chemotherapeutic agents. 
 
 
4. Conclusion 
This study reported the antiproliferative potential of C. aurantium stem bark on four human 
cancer cell lines. In addition, six acridone alkaloids have been reported from C. aurantium stem 
bark. Additionally, the cytotoxicity of natsucitrine-I on any human cancer cell line is reported 
for the first time. The six acridone alkaloids isolated from the active DCM fraction had varying 
cytotoxicity, with citracridone-I displaying highest cytotoxicity across four human carcinoma 
cell lines. The high selectivity displayed by the compounds suggest that the acridone alkaloids 
have potential in the development of low-toxicity chemotherapeutic agents. The cytotoxicity 
of the isolated compounds, may support the ethnomedicinal use of this plant, in the 
management of cancer and other inflammatory diseases. Further study to explore the 
underlying molecular mechanism of the isolated acridone alkaloids is needful. 
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Table 1: Pharmacological activities of Citrus aurantium 
 
Pharmacological 
Activities 
Part used Model Activity References 
Antibacterial Flowers Agar-well 
diffusion assay 
Displayed marked antibacterial activity 
against Pseudomonas aeruginosa, 
Escherichia coli and Listeria monocytogenes 
Ammar et al., 2012 
Anti-inflammatory Fruits Pro-inflammatory 
mediator 
inhibition 
Reduction in protein and mRNA levels of 
COX-2 and iNOS in LPS-stimulated RAW 
264.7 
Kang et al., 2011 
Anti-oxidant Peel, flowers and 
leaf 
DPPH assay Oil of leaves displayed high scavenging 
activity (94.36%) 
Sarrou et al., 2013 
Antiulcer Fruit peels Acetic acid-
induced gastric 
lesion assay. 
Significant reduction in lesion area 
(250mg/kg/day; 76%) within gastric 
compared to the positive control (cimetidine; 
100 mg/kg/day) that only promoted only a 
23% cure rate.  
Polo et al., 2012 
Anxiolytic Fruits Light/dark box 
experiment 
Displayed anxiolytic effects after acute (5 
mg/kg) or 14-day repeated (1 mg/kg/day) 
treatments 
Costa et al., 2013 
Larvicidal Fruit peel Larvicidal 
bioassay 
Remarkable larvicidal activity effect against 
Anopheles stephensi with LC50 value of 31.20 
ppm 
Sanei-Dehkordi et al., 2016 
Smooth muscle 
relaxant 
Flower Barium chloride-
induced 
contraction assay 
Aqueous extract (1-8 mg/mL) induced 
antispasmodic effect mainly via calcium 
influx blockade 
Ahangarpour et al., 2011 
 
Vasodilatory  Flower and fruit 
peel 
Vascular 
contractility assay 
Exerts relaxation effect on precontracted 
mouse aortas through inhibition of Ca2+ 
influx via a cation channel 
Kang et al., 2016 
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Table 2: 1H (600 MHz) NMR assignments for 1-6 in CDCl3. 
Position 1 2 3 4 5 6 
1H, J (Hz) 1H, J (Hz) 1H, J (Hz) 1H, J (Hz) 1H, J (Hz) 1H, J (Hz) 
1 14.04, s 14.32, s 14.30, s 14.51, s 14.43, s 14.30, s 
2 6.41, s 6.29, s 6.27, s 6.24, s 6.24, s 6.12, s 
3 - - - - - - 
4 - - - 6.24, s - - 
4a - - - - - - 
5 - - - - - - 
6 7.14, dd (7.8, 1.4) - 7.33, d (7.9) - - - 
7 7.18, t (7.8) 7.02, d (8.8) 7.19, t (7.9) 6.90, d (8.6) 6.92, d (8.8) 6.92, d (8.8) 
8 7.96, dd (7.8, 1.4) 8.09, d (8.8) 7.94, dd (7.9, 1.2) 8.09, d (8.6) 8.11, d (8.8) 7.73, d (8.8) 
8a - - - - - - 
9  - - - - - 
9a - - - - - - 
10a - - - - - - 
11 - 6.57, d (9.7) 6.70, d (9.7) - - 6.75, d (9.5) 
12 - 5.62, d (9.7) 5.56, d (9.7) - - 5.65, d (9.5) 
13 - - - - - - 
14 - 1.54, s 1.53, s - - 1.54, s 
15 - 1.54, s 1.53, s - - 1.54, s 
NCH3 3.84, s 3.73, s 3.81, s 3.92, s 3.98, s 3.82, s 
3-OCH3 3.82, s - - 3.84, s 3.96, s - 
4-OCH3 3.99, s - - - 3.85, s - 
5-OCH3 - 3.93, s - 3.70, s 3.70, s - 
Assignments were confirmed by DEPT, HSQC and HMBC experiments and by comparing with literature values 
 (Wu and Furukawa, 1983; Wu et al., 1983; Juoichi et al., 1985; Yamamoto et al., 1989; Ono et al., 1995)  
 
28 
 
Table 3: 13C (150 MHz) NMR and DEPTQ assignments for 1-6 in CDCl3. 
Position 1 2 3 4 5 6 
 13C, DEPTQ 13C, DEPTQ 13C, DEPTQ 13C, DEPTQ 13C, DEPTQ 13C, DEPTQ 
1 160.4 164.6 164.6 165.9 159.0 164.0 
2 94.0 98.7 98.2 94.4 87.7 97.0 
3 159.8 161.1 161.4 165.5 156.1 160.9 
4 130.1 102.5 102.3 91.0 130.5 102.5 
4a 142.2 147.2 147.8 147.1 143.1 148.0 
5 146.2 135.8 137.2 134.2 134.4 134.6 
6 120.6 154.4 120.4 154.8 154.7 150.9 
7 123.1 112.0 112.0 111.2 111.7 111.7 
8 118.9 123.4 123.2 124.0 123.9 123.7 
8a 125.1 118.6 117.8 117.3 117.5 117.3 
9 182.4 181.5 182.0 180.4 180.6 181.7 
9a 106.7 106.8 107.3 105.0 105.7 105.9 
10a 137.5 141.5 146.8 138.0 137.9 138.2 
11 - 120.4 120.4 - - 120.7 
12 - 124.7 124.0 - - 117.2 
13 - 77.7 77.4 - - 76.3 
14 - 27.2 27.2 - - 25.9 
15 - 27.2 27.2 - - 25.9 
NCH3 46.3 47.9 48.9 39.2 39.5 47.8 
3-OCH3 60.3 - - 55.6 56.1 - 
4-OCH3 56.8 - - - 60.8 - 
5-OCH3 - 60.1 - 61.7 61.6 - 
Assignments were confirmed by DEPT, HSQC and HMBC experiments and by comparing with literature values  
(Wu and Furukawa, 1983; Wu et al., 1983; Juoichi et al., 1985; Yamamoto et al., 1989; Ono et al., 1995)  
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Table 4: Antiproliferative Effects of the Fractions of the Stem Bark of Citrus aurantium 
against Four Human Cancer Cell Linesa 
 
Fraction 
                                 IC50 (µg/mL)
b     
MCF7  A549 PC3 HepG2 
n-hexane > 100 > 100 > 100 > 100 
DCM 5.12 ±0.54 3.88 ± 0.58 4.72 ± 0.23 5.73 ± 0.99 
MeOH 90.6 ± 4.54 88.9 ± 1.23 78.2 ± 2.14 92.7 ± 4.11 
aMCF7 - human breast cancer cells; A549-  Human lung carcinoma cells; PC3 -  human prostate 
carcinoma cells; HepG2 - human hepatocellular carcinoma cells. bMTT method, with the cells 
incubated with the fractions for 72 h (means ± SEM, n = 3). Vinblastine was used as the positive 
control and reference compound. 
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Table 5: Antiproliferative Effects of Acridone Alkaloids from the Stem Bark of Citrus 
aurantium against Four Human Cancer Cell Linesa 
 
Compound 
                                           IC50 (µM)
b     
MCF7 A549 PC3 HepG2 PNT2  
1 44.53 ± 1.45 35.76 ± 1.55 38.23 ± 1.11 50.74 ± 1.11 179 ± 4.11 
2 12.65 ± 0.54 14.02 ± 0.11 14.88 ± 0.17 22.42 ± 0.17 151.5 ± 6.47 
3 24.03 ± 1.05 25.94 ± 0.61 28.15 ± 0.68 30.09 ± 0.94 190.3 ± 3.81 
4 31.11 ± 1.41 29.69 ± 0.44 27.44 ± 1.61 37.45 ± 0.79 205.1 ± 2.39 
5 26.87 ± 0.57 25.02 ± 1.92 24.29 ± 0.49 26.38 ± 0.12 222.7 ±6.12 
6 20.91 ± 0.17 20.36 ± 0.81 18.23 ± 0.53 32.62 ± 1.02 175.4 ± 2.11 
Vinblastine 0.023 ± 0.01 0.037 ± 0.01 0.028 ± 0.01 0.021 ± 0.01 0.037 ± 0.01 
aMCF7 - human breast cancer cells; A549 - human lung carcinoma cells; PC3 - human prostate 
carcinoma cells; HepG2 - human hepatocellular carcinoma cells; PNT2 - normal human 
prostate cells. bMTT method, with the cells incubated with the fractions for 72 h (means ± 
SEM, n = 3). Vinblastine was used as the positive control and reference compound. 
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Table 6. The Selectivity Index (SI) of 1-6 and Vinblastine (VBN) 
Compound  MCF7 A549 PC3 HepG2 
1 4.01 5.00 4.68 3.52 
2 11.97 10.80 10.18 6.75 
3 7.91 7.33 6.76 6.32 
4 6.59 6.90 7.47 5.47 
5 8.28 8.90 9.16 8.44 
6 8.38 8.61 9.62 5.37 
VBN 1.60 1.00 1.32 1.76 
MCF7 - human breast cancer cells; A549 - Human lung carcinoma cells; PC3 - human prostate 
carcinoma cells; HepG2 - human hepatocellular carcinoma cells. SI is the ratio of the IC50 
values of the compound on PNT2 cells to those in the cancer cell lines. 
